GI
Goki Ishikawa
Managing Executive Officer, H.U. Group Holdings; President & CEO, Fujirebio Holdings, Inc.
fujirebio-diagnosticsTherapeutic Areas
fujirebio-diagnostics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Lumipulse® G β-Amyloid 1-42/1-40 Ratio (Plasma) | Alzheimer's Disease (Amyloid Pathology) | Commercial |
| Lumipulse® G pTau 217/β-Amyloid 1-42 Ratio (Plasma) | Alzheimer's Disease (Amyloid Pathology) | Commercial |
| Lumipulse® G NfL Blood Assay | Neuroaxonal Damage (MS, ALS) | Commercial |
| Lumipulse® G pTau 217 CSF Assay | Alzheimer's Disease (Tau Pathology) | Research Use Only |
| Lumipulse® G sTREM2 Assay | Neuroinflammation | Research Use Only |
| Neuro Expert Toolbox (NExT) | Neurodegenerative Disease Panel | Development/Commercialization |
| PreCursor-M AnoGYN Test | Anal & Vulvar Cancer Precursors (HPV) | Commercial |
| HPV Genotyping Assays | Cervical & HPV-related Cancers | Commercial |